drugset / Trial / NCT02646358
Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
Non-randomizedSingle-groupOpen-label
Summary
This is an open-label study designed to evaluate the effect of renal disease on the pharmacokinetics of vepoloxamer relative to the pharmacokinetics in healthy subjects with normal renal function.
Timeline
- Start
- 2016-01
- Primary completion
- 2016-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vepoloxamer | Small molecule | 15 mg/kg | — |
| Subject | Vepoloxamer | Small molecule | 30 mg/kg | — |